 |
Privacy Policy | Terms & Conditions | Contact Us | Site Map | Important Safety Information |
IndicationVentavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%). |
|
|
|
|
|
|
|
 About the I-neb AADSystem |
|
|
|
|
 |
|
|
 |
|
 Download 20 mcg/mL Medication Order Form |
|
| Download the Ventavis Patient Enrollment Forms |
|
About the I-neb AAD SystemThe I-neb AAD System is a battery-powered pulmonary drug delivery system that makes it possible for patients to take their Ventavis® (iloprost) Inhalation Solution treatments almost anywhere. With up to 40 treatments from a single charge, the I-neb AAD System frees patients from the need to be near an electrical outlet. Because the I-neb AAD System is portable and virtually silent, patients may find it easier to comply with their prescribed dosing regimen. Finally, with Adaptive Aerosol Delivery (AAD) technology, you can be sure that your patients are receiving an accurate dose.
Specifically designed for use with VentavisVariable dosing is acceptable for drugs with a broad therapeutic window (e.g., albuterol and ipratropium bromide); however, Ventavis is a potent prostacyclin analogue with a narrow therapeutic index. Precise, reproducible dosing of Ventavis to every patient is required for the safety and efficacy of the drug.Delivers precise doses to every patientThe system uses AAD technology to precisely and reproducibly deliver Ventavis to every patient, at either dose (2.5 mcg or 5.0 mcg), using a single ampule of medication. The dose each patient receives is controlled by the medication chamber. The I-neb AAD System continuously monitors and analyzes a patient's breathing pattern and delivers pulses of aerosol into the start of each inhalation until the set dose is delivered.One ampule per treatmentOnly one drug treatment (either 2.5 mcg or 5.0 mcg) can be delivered from the contents of a single ampule. Reuse of any drug solution that remains after completing a drug treatment, even if the reservoir is "topped off" with fresh medication, will not give accurate dosing. Do not reuse ampules.Read more about the I-neb ADD System:
IMPORTANT SAFETY INFORMATION Hypotension leading to syncope has been observed; Ventavis should therefore not be initiated in patients with systolic blood pressure less than 85 mmHG. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension. Ventavis inhalation may cause brochospasm and patients with a history of hyperreactive airway disease may be more sensitive. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Ventavis has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants. Please see full Prescribing Information
|
|
||||
| |||||
